Alyeska holds 6.33M shares (4.85%) of Immunic

Immunic, Inc. reports that Alyeska-affiliated reporting persons beneficially own 6,332,000 shares of Common Stock, representing 4.85% of the class.

Rhea-AI Filing Summary

Immunic, Inc. reports that Alyeska-affiliated reporting persons beneficially own 6,332,000 shares of Common Stock, representing 4.85% of the class. The stake, reported as of March 31, 2026, includes 4,041,000 shares issuable upon exercise of warrants and 2,291,000 shares issuable upon exercise of pre-funded warrants. The filing shows shared voting and dispositive power over the 6,332,000 shares. The number of shares outstanding is listed as 130,464,825 per the Form S-3 dated April 2, 2026.

Insights

Institutional Ownership Analyst

Alyeska reports a 4.85% beneficial position in Immunic as of March 31, 2026.

The filing states the reporting persons beneficially own 6,332,000 shares, comprised of 4,041,000 warrants and 2,291,000 pre-funded warrants. Voting and dispositive power over these shares is reported as shared; the filing attributes investment control to Alyeska as manager of the fund.

Holdings are shown against a disclosed share base of 130,464,825 shares from a Form S-3 dated April 2, 2026. This is a passive ownership disclosure under the Schedule 13G/A framework; any trading intentions or timing are not stated in the provided excerpt.

Key Figures

Beneficially owned shares: 6,332,000 shares Percent of class: 4.85% Warrants issuable: 4,041,000 shares +2 more

5 metrics

Beneficially owned shares 6,332,000 shares ownership reported as of March 31, 2026

Percent of class 4.85% calculated using 130,464,825 shares outstanding (Form S-3 dated April 2, 2026)

Warrants issuable 4,041,000 shares issuable upon exercise of warrants

Pre-funded warrants issuable 2,291,000 shares issuable upon exercise of pre-funded warrants

Shares outstanding (reference) 130,464,825 shares per Form S-3 dated April 2, 2026

Key Terms

pre-funded warrants, shared dispositive power, Schedule 13G/A

3 terms

pre-funded warrants financial

"consisting of (i) 4,041,000 shares issuable upon exercise of warrants and (ii) 2,291,000 shares issuable upon exercise of pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shared dispositive power regulatory

"Shared Dispositive Power 6,332,000.00"

Schedule 13G/A regulatory

"FORM TYPE: SCHEDULE 13G/A (Amendment No. 3)"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Alyeska hold in Immunic (IMUX)?

Alyeska-affiliated reporting persons beneficially own 6,332,000 shares, equal to 4.85% of the class as of March 31, 2026. The position combines warrants and pre-funded warrants convertible into common stock.

How is the 6,332,000-share position composed for IMUX?

The disclosed position consists of 4,041,000 shares issuable upon exercise of warrants and 2,291,000 shares issuable upon exercise of pre-funded warrants, as stated in the filing dated March 31, 2026.

Does Alyeska have voting or dispositive power over these IMUX shares?

The filing reports shared voting power and shared dispositive power over the 6,332,000 shares. Alyeska Investment Group, L.P. is identified as exercising voting and investment control for the related fund.

What is the reference share count for Immunic used in the filing?

The filing cites a total common share count of 130,464,825 based on a Form S-3 dated April 2, 2026. That figure is used to calculate the reported 4.85% ownership percentage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:34 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Immunic, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

4525EP101

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 4525EP101

1

Names of Reporting Persons

Alyeska Investment Group, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,332,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,332,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,332,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.85 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 4525EP101

1

Names of Reporting Persons

Alyeska Fund GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,332,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,332,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,332,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.85 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 4525EP101

1

Names of Reporting Persons

Anand Parekh

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,332,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,332,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,332,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.85 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Immunic, Inc.
(b)	Address of issuer's principal executive offices: 1200 Avenue of the Americas, Suite 200, New York, NY 10036
Item 2.
(a)	Name of person filing: (i) Alyeska Investment Group, L.P. (ii) Alyeska Fund GP, LLC (iii) Anand Parekh
(b)	Address or principal business office or, if none, residence: (i) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (ii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (iii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601
(c)	Citizenship: (i) Alyeska Investment Group, L.P. - Delaware (ii) Alyeska Fund GP, LLC - Delaware (iii) Anand Parekh - United States of America
(d)	Title of class of securities: Common Stock, $0.0001 par value
(e)	CUSIP No.: 4525EP101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6,332,000
(b)	Percent of class: 4.85%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 6,332,000
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 6,332,000
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alyeska Investment Group, L.P.

Signature:	Jason Bragg
Name/Title:	Jason Bragg | Chief Financial Officer
Date:	05/15/2026

Alyeska Fund GP, LLC

Signature:	Jason Bragg
Name/Title:	Jason Bragg | Chief Financial Officer
Date:	05/15/2026

Anand Parekh

Signature:	Anand Parekh
Name/Title:	Anand Parekh | Self
Date:	05/15/2026

Exhibit Information

As of March 31, 2026, the Reporting Persons beneficially own 6,332,000 shares of Common Stock, consisting of (i) 4,041,000 shares issuable upon exercise of warrants and (ii) 2,291,000 shares issuable upon exercise of pre-funded warrants. The number of shares of Common Stock outstanding (130,464,825) is based on the Form S-3 dated April 2, 2026. Position held by Alyeska Master Fund, L.P. Alyeska Investment Group, L.P., as investment manager, exercises voting and investment control over the shares held by Alyeska Master Fund, L.P. Anand Parekh, as Chief Executive Officer of Alyeska Investment Group, L.P., may be deemed the beneficial owner of such shares. Mr. Parekh disclaims beneficial ownership of such shares. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.